WO2018011419A3 - Pharmaceutical use of alpha-l-guluronic acid - Google Patents

Pharmaceutical use of alpha-l-guluronic acid Download PDF

Info

Publication number
WO2018011419A3
WO2018011419A3 PCT/EP2017/067920 EP2017067920W WO2018011419A3 WO 2018011419 A3 WO2018011419 A3 WO 2018011419A3 EP 2017067920 W EP2017067920 W EP 2017067920W WO 2018011419 A3 WO2018011419 A3 WO 2018011419A3
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
guluronic acid
pharmaceutical use
acid monomer
uronic acid
Prior art date
Application number
PCT/EP2017/067920
Other languages
German (de)
French (fr)
Other versions
WO2018011419A2 (en
Inventor
Abbas Mirshafiey
Original Assignee
HÄUSLER, Lars
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HÄUSLER, Lars filed Critical HÄUSLER, Lars
Publication of WO2018011419A2 publication Critical patent/WO2018011419A2/en
Publication of WO2018011419A3 publication Critical patent/WO2018011419A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a uronic acid monomer for use in the treatment of immune system disturbances, inflammatory diseases, kidney diseases, allergies and neurodegenerative diseases, wherein the uronic acid monomer is α-L-guluronic acid or a derivative or pharmaceutically acceptable salt thereof, and said uronic acid monomer is administered at a dose of less than 50 mg/kg/day.
PCT/EP2017/067920 2016-07-14 2017-07-14 Pharmaceutical use of alpha-l-guluronic acid WO2018011419A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102016113017.6 2016-07-14
DE102016113017.6A DE102016113017A1 (en) 2016-07-14 2016-07-14 Pharmaceutical use of alpha-L-guluronic acid

Publications (2)

Publication Number Publication Date
WO2018011419A2 WO2018011419A2 (en) 2018-01-18
WO2018011419A3 true WO2018011419A3 (en) 2018-03-08

Family

ID=59581843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/067920 WO2018011419A2 (en) 2016-07-14 2017-07-14 Pharmaceutical use of alpha-l-guluronic acid

Country Status (2)

Country Link
DE (1) DE102016113017A1 (en)
WO (1) WO2018011419A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10247073A1 (en) * 2002-10-09 2004-04-22 Westfälische Wilhelms-Universität Münster Monomeric uronic acid compound production, for use e.g. as immunosuppressive, antirheumatic or cardiovascular agents, by hydrolyzing bacterially produced polyuronic acid

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166137A (en) 1991-03-27 1992-11-24 Nobipols Forskningsstiftelse Guluronic acid polymers and use of same for inhibition of cytokine production
US5952308A (en) 1991-07-29 1999-09-14 Pola Chemical Industries Inc. Mineral absorption promoting agent
KR100501584B1 (en) 2000-02-03 2005-07-18 (주)케이비피 Process for preparing low molecular polymannuronate, a novel use thereof as controller of serum lipids, and functional foods and health-aid foods comprising the same
GB0005743D0 (en) 2000-03-10 2000-05-03 Reckitt & Colmann Prod Ltd Pharmaceutical compositions including alginates
DE10253514A1 (en) * 2002-11-16 2004-05-27 Westfälische Wilhelms-Universität Münster Production of new or known monomeric uronic acid compounds, useful e.g. as immunosuppressive or antiarthritic agents, by hydrolyzing bacterially produced polyuronic acid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10247073A1 (en) * 2002-10-09 2004-04-22 Westfälische Wilhelms-Universität Münster Monomeric uronic acid compound production, for use e.g. as immunosuppressive, antirheumatic or cardiovascular agents, by hydrolyzing bacterially produced polyuronic acid

Also Published As

Publication number Publication date
WO2018011419A2 (en) 2018-01-18
DE102016113017A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
MX2017004592A (en) Pharmaceutical formulations for the oral delivery of peptide or protein drugs.
WO2017132432A8 (en) Benzimidazole derivatives as modulators of ror-gamma
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
WO2016133903A3 (en) Combination therapy for cancer treatment
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MX2021002321A (en) Novel methods.
JP2017506624A5 (en)
WO2018111315A8 (en) PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES
WO2015171965A3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
MX2017015456A (en) Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto.
EP3400964A4 (en) Taste-masked and orally administered pharmaceutical preparation containing varenicline or pharmaceutically acceptable salt thereof
MX2019005309A (en) Anti-bag3 antibodies in combination with inhibitors of immune check-point for therapeutic use.
WO2014111790A3 (en) Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
JP2017061488A5 (en)
MX2016010892A (en) Agent for improving or preventing progression of chronic kidney disease.
EP3586843A4 (en) Glaucocalyxin a derivative, pharmaceutically acceptable salt thereof, or pharmaceutical composition thereof and uses thereof in preparation of drugs for treating psoriasis
WO2015082590A3 (en) Bis-mmf derivatives
MX2019003339A (en) Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof.
WO2018011419A3 (en) Pharmaceutical use of alpha-l-guluronic acid
WO2017034242A3 (en) Novel catechol derivative and pharmaceutical composition comprising same
WO2015165964A8 (en) Treatment and prevention of alzheimer's disease (ad)
MY187270A (en) Renal insufficiency progression inhibitor, prophylactic agent for renal insufficiency and indoxyl sulfate production inhibitor
WO2016122288A3 (en) Combined formulation including verbenone derivative and therapeutic agent for reperfusion for preventing or treating cerebrovascular diseases, arteriosclerosis or cardiovascular disease
TW201613606A (en) Therapeutic drug for chronic renal failure
NZ724678A (en) New use of n,n-bis-2-mercaptoethyl isophthalamide

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE